Mural Oncology (MURA)
Mural Oncology Statistics
Share Statistics
Mural Oncology has 17.23M shares outstanding. The number of shares has increased by 1.8% in one year.
| Shares Outstanding | 17.23M |
| Shares Change (YoY) | 1.8% |
| Shares Change (QoQ) | 0.98% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.34M |
| Failed to Deliver (FTD) Shares | 1.64K |
| FTD / Avg. Volume | 0.61% |
Short Selling Information
The latest short interest is 412.86K, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 412.86K |
| Short % of Shares Out | 2.42% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 3.85 |
Valuation Ratios
The PE ratio is -0.42 and the forward PE ratio is -0.82. Mural Oncology's PEG ratio is 0.01.
| PE Ratio | -0.42 |
| Forward PE | -0.82 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.39 |
| P/FCF Ratio | -0.42 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Mural Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.84, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.84 |
| Quick Ratio | 5.84 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | - |
| Debt / FCF | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.11M |
| Employee Count | 116 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -74.13% in the last 52 weeks. The beta is 5.32, so Mural Oncology's price volatility has been higher than the market average.
| Beta | 5.32 |
| 52-Week Price Change | -74.13% |
| 50-Day Moving Average | 3.44 |
| 200-Day Moving Average | 3.42 |
| Relative Strength Index (RSI) | 19.81 |
| Average Volume (20 Days) | 267.62K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -128.51M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -7.58 |
Balance Sheet
The company has 115.46M in cash and 8.02M in debt, giving a net cash position of 107.44M.
| Cash & Cash Equivalents | 115.46M |
| Total Debt | 8.02M |
| Net Cash | 107.44M |
| Retained Earnings | -159.37M |
| Total Assets | 169.39M |
| Working Capital | 126.72M |
Cash Flow
In the last 12 months, operating cash flow was -128.54M and capital expenditures -92K, giving a free cash flow of -128.64M.
| Operating Cash Flow | -128.54M |
| Capital Expenditures | -92K |
| Free Cash Flow | -128.64M |
| FCF Per Share | -7.59 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MURA is $15, which is 1239.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 1239.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -2.6 |
| Piotroski F-Score | 0 |